Immune Regulation Overview
Latest Deal Type
Later Stage VC
Latest Deal Amount
$5.66M
Immune Regulation General Information
Description
Developer of anti-inflammatory peptides designed to treat immuno-inflammatory diseases resulting from a poorly controlled or overactive immune response. The company's peptides have the ability to significantly advance the control and management of moderate to severe chronic inflammatory diseases, with the potential for diseases modification and remission, enabling patients with immuno-inflammatory diseases like asthma, atopic dermatitis and inflammatory bowel diseases to get better treatment and faster recovery.
Immune Regulation Timeline
Want to dig into this profile?
We’ll help you find what you need
Learn more
Immune Regulation Valuation & Funding
| Deal Type |
Date |
Amount |
Raised to Date |
Post-Val |
Status |
Stage |
| 6. Later Stage VC |
16-May-2018 |
$5.66M |
000.00 |
000.00 |
Completed |
Generating Revenue |
| 5. Later Stage VC |
14-Jun-2017 |
00.000 |
00.00 |
000.00 |
Completed |
Generating Revenue |
| 4. Early Stage VC |
23-Feb-2016 |
00.000 |
00.000 |
000.00 |
Completed |
Generating Revenue |
| 3. Early Stage VC |
28-Jul-2015 |
00000 |
00.000 |
000.00 |
Completed |
Generating Revenue |
| 2. Grant |
|
|
$940K |
|
Completed |
Generating Revenue |
| 1. Angel (individual) |
17-Dec-2014 |
$940K |
$940K |
0000 |
Completed |
Generating Revenue |
Immune Regulation Cap Table
To view Immune Regulation‘s complete cap table, request access >>
| Stock |
# of Shares
Authorized |
Par Value |
Dividend Rate (%) |
Original
Issue Price |
Liquidation |
Liquidation
Pref. Multiple |
Conversion Price |
% Owned |
| Ordinary |
000,000 |
00.000000 |
|
000.00 |
000.00 |
00 |
000.00 |
00.000 |
| Ordinary |
00,000 |
00.000000 |
|
0000.00 |
0000.00 |
00 |
0000.00 |
0.000 |
| Ordinary |
30,530 |
$0.000137 |
|
$123.68 |
$123.68 |
1x |
$123.68 |
1.53% |
Immune Regulation Executive Team (11)
| Name |
Title |
Board Seat |
Contact Info |
| Richard Nagle |
Chief Executive Officer & Board Member |
|
|
| Clare Burgess Ph.D |
Chief Operating Officer |
|
|
| Roly Foulkes Ph.D |
Co-Chief Scientific Officer |
|
|
| David Beadle |
Chief Business Officer & Board Member |
|
|
| Jeannette Watson |
Head of Development |
|
|
4 Former Executives